 Today, I have the pleasure of speaking with Brent Willis from Voyager Pharmaceutical. How are you today? I'm great, Tracy. Thanks for having me on. And of course, of course, with Voyager, we all have the theme model line down from earth to bottle, correct? That's right. Full integration of the radiology drug market. And you just put out some really good news, or at least I perceive it to be good news. I saw an NPV of $344 million directly related to your PEA results. Tell us about your PEA results for us, please. Well, they verified everything we knew that, you know, we have a very special project owning that one of the highest grade barium sulfate deposits in the world allows us to sell a very high end product for high value. And you don't need a whole lot of resource to create high level cash flow and a high net present value over 10 years of $344 million. And what's very impressive about it is the eternal rate of return of 137% out of tax. And it really shows what a great investment Voyager Pharmaceuticals is at this point. And of course, one of the analysts that participated in the investor talk that you just recently hosted wrote me with obviously some very credible players from the pharmaceutical industry sector are taking Voyager seriously based on your recent board announcements. Would you like to talk about this? Well, our scientific advisory board is key for us moving forward on our product development, on our existing generics that we're making. But more importantly on our new products that we're making, next generation contrast products for the industry. And having the top doctors in the world sitting on our board is critical to formulate and test and get their feedback on the performance of these drugs. So it's very critical for a pharmaceutical company to have a really strong scientific advisory board. And we're very happy to have the team what we have in place. Of course, it's my understanding that you are doing some trials right now for processing. Is that correct? Not like clinical trials. What we're doing is we're testing our products within our own staff. We're going to the clinics and we're swallowing our barium. We're running CT scans. That hasn't started yet. It's going to start here in the next three weeks is our plan. And to ensure that our products are working as effectively as possible and equivalent to what's in the marketplace today. And for those of you out there that may not be familiar with barium, would you like just to touch really briefly on the issues around barium and how it's controlled currently our global supply? Currently there's a very limited supply of a natural occurring high purity barium sulfates. We have the only deposit that we know of that is grading over 98% barium sulfates. All other products is synthetically man-made and it's very expensive. So being able to mine it for mother nature, it's obviously our costs are much lower. And that's what gives us the competitive advantage in the high-end barium market moving forward. The publisher for Investor Intel, Jack Lipton was telling me that mining might be incorrect for people to truly appreciate where this barium is and that you don't actually have to mine it. It's closer to surface. Can you talk to me a little bit about this? Yeah, there's a difference between a mine and a quarry and we're a quarry. So we don't have any leachable minerals. We don't have anything other than barium sulfate and dolomite. It's very much like a gravel pit. So it's easy to permit. Our environmental hurdles are very low and we expect permitting on our quarry permitting to advance quite quickly after we do our bulk sample. And so what should we as investors and shareholders anticipate say in the upcoming quarter? What are we looking forward to right now? Because you've got a wide spectrum of objectives based on what I have read. Well, working with the FDA is number one. We are doing our pre-submission and after that we will be submitting our device applications for licensing in the United States. That's a major milestone that's coming down the pipeline here. In the next two to three quarters, we think it will should come to fruition. We're looking at sales into Canada, which will happen the next couple quarters with our initial batch runs that will go to market and test market and we'll be reaching out to provincial health authorities to begin bidding our products into the Canadian market. Well, Brent, what I would love because we're all following and watching what you're doing is every time you achieve one of these milestones, let's get an investor intel update so that we can all follow Voyager Pharmaceuticals. Excellent. I love that. Thank you. Thank you, Brent.